Natera Inc. (NASDAQ:NTRA) is one of the best growth stocks to buy now. On September 30, Natera announced the publication of a validation study for its personalized molecular residual disease test, Signatera, in the Journal of Clinical Oncology – Precision Oncology/JCO PO. The peer-reviewed manuscript features results from the largest-ever ctDNA study in testicular cancer and showed that Signatera outperformed standard-of-care serum tumor markers/STMs in prognostic evaluation.
The multicenter, retrospective study evaluated circulating tumor DNA/ctDNA as a prognostic biomarker for patients with germ cell tumors/GCTs, specifically testicular cancer, which accounts for ~95% of all GCTs and is the most common malignancy in men aged 15-35. The study analyzed 324 plasma samples from 74 patients with testicular cancer across stages I-III.
Signatera was used to assess ctDNA levels before, during, and after treatment to determine its association with event-free survival. Testicular cancer management is often complicated by the limited utility of conventional STMs, which can lead to unnecessary chemotherapy. Findings showed that Signatera-positivity was significantly associated with shorter EFS, highlighting its unique value to reliably detect molecular residual disease and predict clinical outcomes.
Natera Inc. is a diagnostics company that provides molecular testing services worldwide. It serves independent laboratories, national & regional reference laboratories, medical centers & physician practices, research laboratories, and pharmaceutical companies.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
